Boryung Corporation (KRX:003850)
South Korea · Delayed Price · Currency is KRW 8,510.00
-260.00 (-2.96%)
Sep 17, 2026, 3:30 PM KST
Boryung Revenue
Boryung had revenue of 279.62B KRW in the quarter ending June 30, 2026, with 11.17% growth. This brings the company's revenue in the last twelve months to 1.06T, up 3.95% year-over-year. In the year 2025, Boryung had annual revenue of 1.02T with 0.03% growth.
Revenue (ttm)
1.06T
Revenue Growth
+3.95%
P/S Ratio
0.68
Revenue / Employee
691.67M
Employees
1,533
Market Cap
715.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.02T | 320.69M | 0.03% |
| Dec 31, 2024 | 1.02T | 157.48B | 18.32% |
| Dec 31, 2023 | 859.63B | 99.15B | 13.04% |
| Dec 31, 2022 | 760.48B | 133.20B | 21.23% |
| Dec 31, 2021 | 627.28B | 65.41B | 11.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Daewoong | 2.12T |
| GC Biopharma | 1.96T |
| Chong Kun Dang Pharmaceutical | 1.78T |
| Daewoong Pharmaceutical | 1.64T |
| Dong-A Socio Holdings | 1.52T |
| Dong-A ST | 860.94B |
| JW Pharmaceutical | 820.86B |
| Ildong Pharmaceutical | 582.33B |